Autologous Blood Transfusion for Postoperative Hemorrhage
Trial Summary
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Research shows that using a patient's own blood (autologous blood transfusion) during surgeries like hip replacement and cardiac surgery can reduce the need for donor blood and improve blood clotting, which may help manage bleeding after surgery.
12345Autologous blood transfusion, where a person receives their own blood, is considered the safest type of blood transfusion when guidelines are followed. It reduces the risk of infections and immune reactions compared to donor blood, although some minor adverse reactions can still occur.
14678Fresh Autologous Whole Blood Transfusion is unique because it uses the patient's own blood, collected and reinfused during or after surgery, reducing the risk of infections and complications associated with donor blood. This method is considered the safest form of transfusion and can be used in various surgical settings to minimize the need for donor blood.
1391011Eligibility Criteria
This trial is for adults aged 18 to 90 who can consent, are open to blood transfusions, and are scheduled for elective heart surgery with cardiopulmonary bypass. It's not for those who've had a recent blood transfusion, are unstable with low blood pressure or high heart rate, have an active infection or sepsis, or very low hemoglobin.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pre-operative
Collection of autologous blood before cardiopulmonary bypass for transfusion after CPB
Treatment
Transfusion of fresh autologous whole blood versus standard of care expectant management of bleeding during elective cardiac surgery
Post-operative Monitoring
Monitoring for complications such as myocardial infarction, heart failure, and other secondary outcomes
Follow-up
Participants are monitored for safety and effectiveness after treatment
Participant Groups
Fresh Autologous whole Blood is already approved in United States, European Union, Canada for the following indications:
- Cardiac surgery
- Elective surgeries with high risk of bleeding
- Cardiac surgery
- Elective surgeries with high risk of bleeding
- Rare blood types or specific blood matching needs
- Cardiac surgery
- Elective surgeries with high risk of bleeding
- Patients with specific blood matching needs